| scholarly article | Q13442814 |
| P50 | author | William Hollingworth | Q47267098 |
| Polly A Newcomb | Q89454622 | ||
| P2093 | author name string | David Blough | |
| Catherine Fedorenko | |||
| Scott Ramsey | |||
| Karen Overstreet | |||
| Anne Kirchhoff | |||
| Karma Kreizenbeck | |||
| Kyle Snell | |||
| P2860 | cites work | Medical Bankruptcy in the United States, 2007: Results of a National Study | Q22252535 |
| Personal bankruptcy after traumatic brain or spinal cord injury: the role of medical debt | Q36183836 | ||
| The risk of bankruptcy before and after brain or spinal cord injury: a glimpse of the iceberg's tip. | Q43411423 | ||
| Cancer survivors and unemployment: a meta-analysis and meta-regression. | Q45734696 | ||
| The (interconnected) reasons elder Americans file consumer bankruptcy | Q47396047 | ||
| Medical bankruptcy in Massachusetts: has health reform made a difference? | Q48570810 | ||
| Indirect economic effects of long-term breast cancer survival. | Q50107998 | ||
| The financial burden of cancer: estimates from a study of insured women with breast cancer. | Q50747997 | ||
| The personal financial burden of cancer for the working-aged population. | Q51138512 | ||
| Breast cancer survival, work, and earnings. | Q52944075 | ||
| Employment pathways in a large cohort of adult cancer survivors. | Q53626769 | ||
| Medical expense as a factor in bankruptcy | Q68404787 | ||
| National estimates of medical costs incurred by nonelderly cancer patients | Q76382047 | ||
| Managing medical bills on the brink of bankruptcy | Q84645599 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| cancer diagnosis | Q110324059 | ||
| P304 | page(s) | 1143-1152 | |
| P577 | publication date | 2013-05-15 | |
| P1433 | published in | Health Affairs | Q260110 |
| P1476 | title | Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis | |
| P478 | volume | 32 |
| Q57168648 | "It still affects our economic situation": long-term economic burden of breast cancer and lymphedema |
| Q38995388 | A Systematic Review of Financial Toxicity Among Cancer Survivors: We Can't Pay the Co-Pay. |
| Q37334558 | A Touchy Subject: Can Physicians Improve Value by Discussing Costs and Clinical Benefits With Patients? |
| Q38748893 | A brighter future? The impact of insurance and socioeconomic status on cancer outcomes in the USA: a review. |
| Q34731391 | A composite measure of personal financial burden among patients with stage III colorectal cancer |
| Q42700925 | A global comparison of the cost of patented cancer drugs in relation to global differences in wealth |
| Q103834988 | A national cross-sectional survey of financial toxicity among bladder cancer patients |
| Q97538192 | A review of access to cancer facilities in Punjab, Pakistan |
| Q48120147 | A user's guide to non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). |
| Q31156878 | Access to Cancer Care and General Medical Care Services Among Cancer Survivors in the United States: An Analysis of 2011 Medical Expenditure Panel Survey Data |
| Q52809531 | Accurate Measurement of Financial Toxicity Is a Prerequisite to Finding a Remedy. |
| Q93109670 | Addressing the Financial Burden of Cancer Clinical Trial Participation: Longitudinal Effects of an Equity Intervention |
| Q37240851 | American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. |
| Q30847275 | Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival. |
| Q37137935 | Association of Financial Strain With Symptom Burden and Quality of Life for Patients With Lung or Colorectal Cancer |
| Q58657168 | Balancing the Economics and Ethics of Personalised Oncology |
| Q91989118 | Breast cancer survivorship care beyond local and systemic therapy |
| Q43466894 | Bridging the gap between financial distress and available resources for patients with cancer: a qualitative study. |
| Q50069897 | Can Patients Afford to Be Adherent to Expensive Oral Cancer Drugs?: Unintended Consequences of Pharmaceutical Development. |
| Q38977216 | Cancer in the Medically Underserved Population |
| Q46896087 | Cancer survivors' experiences with insurance, finances, and employment: results from a multisite study |
| Q92614612 | Changes in Age Distribution of Obesity-Associated Cancers |
| Q36923839 | Chemotherapy Use in the Months Before Death and Estimated Costs of Care in the Last Week of Life. |
| Q47308431 | Chemotherapy use, end-of-life care, and costs of care among patients diagnosed with Stage IV pancreatic cancer |
| Q43248967 | Clinical Trials, Disparities, and Financial Burden: It's Time to Intervene |
| Q50419892 | Coming of Age With Cancer: Physical, Social, and Financial Barriers to Independence Among Emerging Adult Survivors |
| Q28660929 | Commentary: "the Lake Wobegon effect, a natural human tendency to overestimate one's capabilities" (Wikipedia) |
| Q61806205 | Comorbidity is associated with higher risk of financial burden in Medicare beneficiaries with cancer but not heart disease or diabetes |
| Q47551703 | Consumer credit as a novel marker for economic burden and health after cancer in a diverse population of breast cancer survivors in the USA. |
| Q92515507 | Conversations About Financial Issues in Routine Oncology Practices: A Multicenter Study |
| Q90671646 | Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer |
| Q50121469 | Cost of Care for the Initial Management of Ovarian Cancer. |
| Q99628789 | Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer |
| Q37405954 | Cost-minimization analysis of adjuvant chemotherapy regimens given to patients with colorectal cancer in Japan |
| Q64253003 | Cytomorphology of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features and the Impact of New Nomenclature on Molecular Testing |
| Q90000676 | Development and validation of a patient-reported outcome tool to assess cancer-related financial toxicity in Italy: a protocol |
| Q36134855 | Development of prognostic signatures for intermediate-risk papillary thyroid cancer |
| Q36101426 | Disparities in barriers to follow-up care between African American and White breast cancer survivors. |
| Q47618634 | Distress and Financial Distress in Adults With Cancer: An Age-Based Analysis |
| Q40427977 | Do Patients and Oncologists Discuss the Cost of Cancer Treatment? An Observational Study of Clinical Interactions Between African American Patients and Their Oncologists |
| Q40327176 | Do cancer survivors change their prescription drug use for financial reasons? Findings from a nationally representative sample in the United States. |
| Q96952743 | Does Medicare Coverage Improve Cancer Detection and Mortality Outcomes? |
| Q33756769 | Dynamic Assessment of Value During High-Cost Cancer Treatment: A Response to American Society of Clinical Oncology and European Society of Medical Oncology |
| Q42693274 | ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of anti-neoplastic medicines in countries outside of Europe |
| Q39582489 | Economic Analysis Comparing Dalteparin to Vitamin K Antagonists to Prevent Recurrent Venous Thromboembolism in Patients With Cancer Having Renal Impairment |
| Q35886444 | Economic evaluation of therapeutic cancer vaccines and immunotherapy: a systematic review |
| Q45021161 | Economic recovery: A measure of the quality of cancer treatment and survivorship? |
| Q52688845 | Employment benefits and job retention: evidence among patients with colorectal cancer. |
| Q41707697 | Encapsulated follicular variant of papillary thyroid cancer: are these tumors really benign? |
| Q38645289 | Engaging patients in complex clinical decision-making: Successes, pitfalls, and future directions |
| Q50574503 | Estimating regimen-specific costs of chemotherapy for breast cancer: Observational cohort study. |
| Q39080255 | Evidence for overuse of medical services around the world |
| Q38754489 | Evolving molecularly targeted therapies for advanced-stage thyroid cancers |
| Q38602628 | Exploring barriers to the receipt of necessary medical care among cancer survivors under age 65 years. |
| Q91267187 | Factors influencing prostate cancer treatment decisions for African American and white men |
| Q36788307 | Financial Burden of Cancer Clinical Trial Participation and the Impact of a Cancer Care Equity Program |
| Q34968913 | Financial Burden of Pediatric Cancer for Patients and Their Families |
| Q90566551 | Financial Burdens of Cancer Treatment: A Systematic Review of Risk Factors and Outcomes |
| Q27313318 | Financial Concerns About Participation in Clinical Trials Among Patients With Cancer |
| Q37384175 | Financial Distress in Cancer Patients |
| Q36914430 | Financial Hardship Associated With Cancer in the United States: Findings From a Population-Based Sample of Adult Cancer Survivors |
| Q38538110 | Financial Hardship--an Unwanted Consequence of Cancer Treatment |
| Q38984073 | Financial Hardships Experienced by Cancer Survivors: A Systematic Review. |
| Q55425823 | Financial Impact of Breast Cancer in Black Versus White Women. |
| Q61896687 | Financial Impact of Complex Cancer Surgery in India: A Study of Pancreatic Cancer |
| Q37065603 | Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer |
| Q89896835 | Financial Toxicity |
| Q42319245 | Financial Toxicity and Societal Costs of Cancer Care: Distinct Problems Require Distinct Solutions |
| Q47572723 | Financial Toxicity in Patients with Bladder Cancer: Reasons for Delay in Care and Effect on Quality of Life |
| Q48275458 | Financial Toxicity: A Common but Rarely Discussed Treatment Side Effect |
| Q92957789 | Financial Toxicity: A Severe But Underrecognized Side Effect for Cancer Patients |
| Q91644991 | Financial burden amongst cancer patients treated with curative intent surgery alone |
| Q91627108 | Financial burden and quality of life among early-onset colorectal cancer survivors: A qualitative analysis |
| Q94585285 | Financial hardship in Chinese cancer survivors |
| Q64917850 | Financial toxicity - An overlooked side effect. |
| Q55265302 | Financial toxicity and implications for cancer care in the era of molecular and immune therapies. |
| Q54762419 | Financial toxicity in cancer care-Edging toward solutions. |
| Q91749297 | Financial toxicity in gynecologic oncology |
| Q89662670 | Financial toxicity: An adverse effect worthy of a black box warning? |
| Q38924370 | For Working-Age Cancer Survivors, Medical Debt And Bankruptcy Create Financial Hardships |
| Q37099951 | For uninsured cancer patients, outpatient charges can be costly, putting treatments out of reach |
| Q53939535 | From the Guest Editor: The Affordable Care Act and Cancer Care. |
| Q46160844 | Future cancer research priorities in the USA: a Lancet Oncology Commission |
| Q40265406 | Geographic disparities amongst patients with gynecologic malignancies at an urban NCI-designated cancer center |
| Q64901703 | Going for Broke: A Longitudinal Study of Patient-Reported Financial Sacrifice in Cancer Care. |
| Q38255974 | Health technology assessment of cancer drugs in Canada, the United Kingdom and Australia: should the United States take notice? |
| Q64896551 | Health-Related Quality of Life: The Impact on Morbidity and Mortality. |
| Q40293660 | Healthcare Expenditure Burden Among Non-elderly Cancer Survivors, 2008-2012. |
| Q35168777 | Household net worth, racial disparities, and hormonal therapy adherence among women with early-stage breast cancer |
| Q48078636 | Identifying cancer patients who alter care or lifestyle due to treatment-related financial distress |
| Q90533408 | Impact of Cost on the Safety of Cancer Pharmaceuticals |
| Q44430478 | Impact of Medicare Part D on out-of-pocket drug costs and medical use for patients with cancer |
| Q90430426 | Impact of the Patient Protection and Affordable Care Act on cost-related medication underuse in nonelderly adult cancer survivors |
| Q40343211 | Impact of universal health coverage on suicide risk in newly diagnosed cancer patients: Population-based cohort study from 1985 to 2007 in Taiwan |
| Q90458932 | Improving access to cancer clinical trials by reducing the financial burden |
| Q34246580 | Institute of medicine recommendations for improving the quality of cancer care: what do they mean for the general internist? |
| Q90051057 | Insurance Coverage, Employment Status, and Financial Well-Being of Young Women Diagnosed with Breast Cancer |
| Q92281810 | Is Cancer History Associated With Assets, Debt, and Net Worth in the United States? |
| Q37042555 | Is the routine use of bevacizumab in the treatment of women with advanced or recurrent cancer of the cervix sustainable? |
| Q35920196 | It's time to have 'the talk': cost communication and patient-centered care |
| Q89992911 | Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost |
| Q37702339 | Long-term financial burden of breast cancer: experiences of a diverse cohort of survivors identified through population-based registries |
| Q89471287 | MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial |
| Q43848922 | Medical costs and productivity losses of cancer survivors--United States, 2008-2011. |
| Q64132106 | Medical financial hardship among cancer survivors in the United States |
| Q33756382 | Medicare D Subsidies and Racial Disparities in Persistence and Adherence With Hormonal Therapy |
| Q39177943 | Mental distress and health care use among survivors of adolescent and young adult cancer: A cross-sectional analysis of the National Health Interview Survey. |
| Q37350878 | Mind the Gap: Why Closing the Doughnut Hole Is Insufficient for Increasing Medicare Beneficiary Access to Oral Chemotherapy |
| Q48304666 | Molecular genotyping of the non-invasive encapsulated follicular variant of papillary thyroid carcinoma. |
| Q92397937 | National trends, outcomes, and costs of radiation therapy in the management of low- and high-intermediate risk endometrial cancer |
| Q47619243 | Oncology navigators' perceptions of cancer-related financial burden and financial assistance resources |
| Q52617829 | Optimal pain management for patients with cancer in the modern era. |
| Q38810189 | Oral Chemotherapy in Patients with Hematological Malignancies-Care Process, Pharmacoeconomic and Policy Implications |
| Q88810858 | Out-of-Pocket Spending Not Associated with Oral Oncolytic Survival Benefit |
| Q39149082 | Out-of-Pocket Spending and Financial Burden Among Medicare Beneficiaries With Cancer |
| Q47320959 | Papillary Thyroid Cancer: The Good and Bad of the "Good Cancer". |
| Q53757763 | Patient Financial Assistance Programs: A Path to Affordability or a Barrier to Accessible Cancer Care? |
| Q53408967 | Patient Protection and Affordable Care Act Medicaid expansion and gains in health insurance coverage and access among cancer survivors. |
| Q90317119 | Patient-Centered Oncology or Population-Centered Oncology-Which Do We Want, and Which Tradeoffs Are We Willing To Accept? |
| Q35866144 | Patients and Physicians Can Discuss Costs of Cancer Treatment in the Clinic. |
| Q88215126 | Patterns in Health Care Access and Affordability Among Cancer Survivors During Implementation of the Affordable Care Act |
| Q36824126 | Patterns of Colorectal Cancer Care in the United States: 1990-2010. |
| Q30276194 | Patterns of cancer screening, incidence and treatment disparities in China: protocol for a population-based study |
| Q35210611 | Population-based assessment of cancer survivors' financial burden and quality of life: a prospective cohort study |
| Q36862908 | Predictors of financial difficulties and work modifications among cancer survivors in the United States |
| Q36751083 | Pricey pills for an even pricier problem |
| Q45212989 | Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop. |
| Q35638973 | Quality of Life and Cost of Care at the End of Life: The Role of Advance Directives |
| Q35916635 | Race and Insurance Differences in the Receipt of Adjuvant Chemotherapy Among Patients With Stage III Colon Cancer |
| Q90295888 | Racial differences in employment and cost-management behaviors in patients with metastatic breast cancer |
| Q38365026 | Recurrence of papillary thyroid cancer after optimized surgery |
| Q37240919 | Relationships Among Financial Distress, Emotional Distress, and Overall Distress in Insured Patients With Cancer |
| Q39156080 | Rising Prices of Targeted Oral Anticancer Medications and Associated Financial Burden on Medicare Beneficiaries |
| Q37698221 | Self-reported financial burden and satisfaction with care among patients with cancer |
| Q39908855 | Self-reported financial burden of cancer care and its effect on physical and mental health-related quality of life among US cancer survivors. |
| Q38807505 | Societal responsibility and moral hazard: How much are we willing to pay for quality-adjusted life? |
| Q39161081 | The "value" of value in gynecologic oncology practice in the United States: Society of Gynecologic Oncology evidence-based review and recommendations |
| Q36030255 | The Impact of Subclinical Disease and Mechanism of Detection on the Rise in Thyroid Cancer Incidence: A Population-Based Study in Olmsted County, Minnesota During 1935 Through 2012 |
| Q53066788 | The Impact of the Affordable Care Act on North Carolinian Breast Cancer Patients Seeking Financial Support for Treatment. |
| Q30809363 | The State of Cancer Care in America, 2016: A Report by the American Society of Clinical Oncology |
| Q39241834 | The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy |
| Q30248999 | The changing incidence of thyroid cancer |
| Q95936639 | The changing landscape of cancer in the USA - opportunities for advancing prevention and treatment |
| Q38831911 | The changing landscape of papillary thyroid cancer: Epidemiology, management, and the implications for patients |
| Q42392412 | The cost and value of cancer drugs - are new innovations outpacing our ability to pay? |
| Q36895079 | The cost of cancer: a retrospective analysis of the financial impact of cancer on young adults |
| Q38222371 | The development of a financial toxicity patient-reported outcome in cancer: The COST measure |
| Q48234920 | The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment. |
| Q38255597 | The financial burden of cancer care: do patients in the US know what to expect? |
| Q39209934 | The growing burden of cancer in India: epidemiology and social context |
| Q38909657 | The high price of anticancer drugs: origins, implications, barriers, solutions |
| Q42850601 | The imperative to address the cost of oncology care |
| Q63197417 | The intersection of financial toxicity and family building in young adult cancer survivors |
| Q92612903 | The long-term effects of cancer survivorship on household assets |
| Q89120047 | The need to assess financial adverse events |
| Q48074336 | The personal financial burden of complications after colorectal cancer surgery |
| Q89305923 | The role of universal health coverage in reducing cancer deaths and disparities |
| Q33648181 | The thyroid cancer policy model: A mathematical simulation model of papillary thyroid carcinoma in The U.S. population |
| Q26777603 | Thyroid Growth and Cancer |
| Q38670797 | Thyroid cancer in adolescents and young adults |
| Q64950666 | Thyroid cancer risk in airline cockpit and cabin crew: a meta-analysis. |
| Q89460190 | Thyroid cancer: Overdiagnosis of papillary carcinoma - who benefits? |
| Q38783191 | Thyroid nodules and cancer management guidelines: comparisons and controversies |
| Q88946144 | Total and out-of-pocket expenditures among women with metastatic breast cancer in low-deductible versus high-deductible health plans |
| Q47564977 | Trading Bankruptcy for Health: A Discrete-Choice Experiment. |
| Q40098790 | Treatment Costs of Breast Cancer Among Younger Women Aged 19-44 Years Enrolled in Medicaid |
| Q49716701 | Trends in Financial Access to Prescription Drugs Among Cancer Survivors. |
| Q90395986 | Unmet need for clinician engagement regarding financial toxicity after diagnosis of breast cancer |
| Q37167698 | Utilization of Pharmaceutical Patient and Prescription Assistance Programs via a Pharmacy Department Patient Assistance Program for Indigent Cancer Patients |
| Q50053475 | Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States. |
| Q50006724 | With Colorectal Cancer Treatment, Physical Toxicity Is Not the Only Concern. |
Search more.